Introduction
Acute graft-versus-host disease (GVHD) is a life-threatening complication after allogeneic hematopoietic cell transplantation (allo-HCT). About 50% of patients with severe acute GVHD fail to respond to corticosteroids, and steroid-refractory severe GVHD has a dismal prognosis with a 1-year survival rate of less than 20% (1) . GVHD was classically considered to involve only the skin, the intestinal tract, and the liver, which was defined as the "tissue tropism of acute GVHD." However, there is increasing evidence that the effects of acute GVHD are not limited to the 3 classical target organs, but can also occur in the central nervous system (CNS). Animal studies showed that the transfer of allogeneic T cells caused CNS infiltration by effector memory T cells during GVHD and apoptosis in neurons, as well as reduced exploratory activity, spatial learning, and memory, in the recipi-ent mice (2) . Evidence for CNS-GVHD was not restricted solely to the murine model, as other investigators reported that CNS infiltration by CD8 + T cells was a key feature of GVHD in nonhuman primates (3) . Conversely, treatment of primates with immunoprophylaxis after allo-HCT reduced the abundance of T cell infiltration into the brain (3) . Consistent with findings in preclinical models, human brain analysis of female sex-mismatched bone marrow transplant recipients has identified cell infiltrates derived from Y chromosome + donors (4) . In agreement with the occurrence of CNS-GVHD in patients, neurological deficits and MRI findings have been reported in patients developing GVHD (5) .
The role of microglia for CNS inflammation during GVHD has remained unclear. Here we show, for the first time to our knowledge, that GVHD caused activation of microglia cells. Based on selective genetic ablation of TGF-β-activated kinase-1 (TAK1) or tumor necrosis factor (TNF) in microglia, we identify the TAK1/TNF/MHC-II axis as a central mediator of CNS inflammation. In a translational approach, we show that TAK1 inhibition reduces GVHD-induced neurotoxicity in mice, which provides a scientific rationale for testing this approach in a phase I trial in humans.
Acute graft-versus-host disease (GVHD) can affect the central nervous system (CNS). The role of microglia in CNS-GVHD remains undefined. In agreement with microglia activation, we found that profound morphological changes and MHC-II and CD80 upregulation occurred upon GVHD induction. RNA sequencing-based analysis of purified microglia obtained from mice with CNS-GVHD revealed TNF upregulation. Selective TNF gene deletion in microglia of Cx3cr1 creER Tnf fl/mice reduced MHC-II expression and decreased CNS T cell infiltrates and VCAM-1 + endothelial cells. GVHD increased microglia TGF-β-activated kinase-1 (TAK1) activation and NF-κB/p38 MAPK signaling. Selective Tak1 deletion in microglia using Cx3cr1 creER Tak1 fl/fl mice resulted in reduced TNF production and microglial MHC-II and improved neurocognitive activity. Pharmacological TAK1 inhibition reduced TNF production and MHC-II expression by microglia, Th1 and Th17 T cell infiltrates, and VCAM-1 + endothelial cells and improved neurocognitive activity, without blocking graft-versus-leukemia effects. Consistent with these findings in mice, we observed increased activation and TNF production of microglia in the CNS of GVHD patients. In summary, we prove a role for microglia in CNS-GVHD, identify the TAK1/TNF/MHC-II axis as a mediator of CNS-GVHD, and provide a TAK1 inhibitor-based approach against GVHD-induced neurotoxicity.
total-body irradiation (Supplemental Figure 1D ). To characterize the transcriptional profile of microglia under GVHD conditions, we next isolated microglia based on CD11b and CD45 lo expression from mice undergoing allo-HCT versus syn-HCT. RNA-Seq analysis showed close clustering of individual samples belonging to 1 group ( Figure 2C ). Microglia isolated from mice developing GVHD displayed a strong upregulation of genes involved in antigen presentation, in comparison with untreated mice or mice that had undergone syn-HCT ( Figure 2D ). In line with the RNA-Seq results, the microglia cells (CD11b + CD45 lo ) expressed higher protein levels of MHC-II and CD80 on their surface, which have both been shown to be activation and maturation markers of myeloid cells (Figure 2 , E-H). We also observed reduced expression of CX3CR1 on microglia upon GVHD induction ( Figure 2 , I and J) which is consistent with reports showing that this chemokine receptor declines on microglia upon activation (7) .
Microglia cells exhibit increased TNF production upon CNS-GVHD, and genetic deletion of TNF in microglia reduces disease activity. To further characterize the transcriptome of the activated microglia cells under GVHD conditions, we next analyzed their cytokine expression in mice undergoing allo-HCT versus syn-HCT. RNA-Seq analysis showed that multiple proinflammatory cytokines increased in microglia cells from the allo-HCT group ( Figure 3A) . A major GVHD-related cytokine that can mediate local cytotoxic effects is TNF. We hypothesized that TNF could be responsible for local tissue damage in the CNS because of its cytotoxic activity. To validate the findings on the protein levels, we next analyzed microglia by flow cytometry and found increased TNF production in mice that underwent allo-HCT compared with the syn-HCT group (Figure 3 , B and C).
To probe whether microglial TNF plays a functional role in CNS-GVHD, we next induced GVHD in Cx3cr1 creER Tnf fl/mice, which lack TNF in microglia. The Cx3cr1 creER model was chosen because, following tamoxifen-induced gene deletion, short-living peripheral CX3CR1 + monocytes and DCs are rapidly replenished within 4 weeks of tamoxifen induction and hence re-express the target gene, while in contrast the long-living microglia cells maintain the gene deletion (6) . We found that Cx3cr1 creER Tnf fl/mice exhibited lower frequencies of CD3 + cells in the cortex and meninges compared with littermate controls (Figure 3 , D-F). RNA-Seq of microglia showed a reduction of Tnf, confirming the gene ablation, as well as of Cd74 and MHC-II (H2-Eb1) in Cx3cr1 creER Tnf fl/mice compared with littermate controls ( Figure 3G ).
These studies identify TNF as a major pathogenic cytokine in CNS-GVHD based on unbiased RNA-Seq of microglia and functional gene deletion using the Cre-lox system.
GVHD enhances proinflammatory MAPK/NF-κB/TAK1 signaling in microglia cells. Since TNF, IL-6, IL-12, IL-18, and IL-1β, which we had found in the RNA-Seq analysis of the microglia, activate various signaling cascades in immune cells, we next aimed at understanding which signaling events were responsible for the observed microglia activation. Transcriptome analysis of microglia showed upregulation of multiple signaling molecules, including Map3k7, encoding TGF-β-activated kinase-1 (TAK1) ( Figure 4A ). In agreement with this upregulation, we found increased phosphorylation of p38 MAPK, indicating the activation of the MAPK/NF-κB signaling pathway, in mice developing CNS-GVHD ( Figure 4 , B and C).
Results

Microglia activation and expansion are features of CNS-GVHD.
To determine whether GVHD induction in our models caused T cell infiltration into the CNS as a characteristic feature of CNS-GVHD (2), we analyzed the brains of mice that underwent syngeneic HCT (syn-HCT) or allogeneic HCT (allo-HCT). The abundance of CD3 + T cells increased in the cortex and the meninges of mice that underwent allo-HCT, but not syn-HCT ( Figure 1 , A-D). Allo-HCT also led to an increased frequency of CD11b + CD45 hi cells ( Figure 1 , E and F). The CD11b + CD45 hi cells in the CNS of mice undergoing allo-HCT included dendritic cells, macrophages, and monocytes (Supplemental Figure 1A ; supplemental material available online with this article; https://doi.org/10.1172/ JCI130272DS1). Of these myeloid cells, monocytes were most abundant with a median of 23% (range 3%-35%) of the CD11b + CD45 hi cells. To quantify the contribution of donor-derived monocytes to the increased TNF production and MHC-II expression, we used donor mice lacking CCR2, which exhibit reduced monocyte migration. We observed no reduction of TNF production or MHC-II expression in the group that had received the bone marrow graft from CCR2 -/donors (Supplemental Figure 1 , B and C).
Hence we next analyzed the morphology of microglia cells. We observed that the filament dendrite length and the numbers of dendrite segments, branching points, and dendrite terminal points declined in mice that developed GVHD compared with mice that underwent syn-HCT or untreated mice (Figure 1 , G-K). Comparable morphological changes have been previously reported as features of microglia activation in autoimmune disease of the CNS (6). In aggregate these findings show that profound morphological changes indicative of microglia activation occur upon CNS-GVHD induction.
MHC class II and CD80 expression is increased on microglia cells of mice developing GVHD. The CNS of mice undergoing allo-HCT harbored increased numbers of Iba-1 + microglia cells on day 14 after allo-HCT compared with syn-HCT ( Figure 2 , A and B). Conversely, the microglia decreased on day 7 in both groups receiving cells to increasing TNF concentrations. We observed that TNF caused activation of TAK1, JNK, and p65 (Figure 4 , D-I). In agreement with this result, IκB was increasingly degraded, a sign of higher NF-κB activity ( Figure 4J ). These findings show that the TAK1/NF-κB signaling cascade is active in microglia and can be induced in vitro by TNF exposure.
This finding is consistent with our observation that TNF expression is increased in microglia and with published data showing that TAK1/NF-κB signaling triggers TNF production (8) . TNF can be induced by NF-κB signaling but can also by itself amplify NF-κB pathway activity. Therefore, we studied the effect of TNF on NF-κB signaling in microglia in vitro by exposing the Deletion of TAK1 in microglia reduces CNS-GVHD. It was previously shown that upon stimulation TAK1 and its adaptors -TAB2, TAB3, and NEMO -are recruited to the polyubiquitinated receptor-interacting (TNFSF-interacting) serine-threonine kinase 1 (RIPK1), in turn allowing TAK1 to phosphorylate and activate the catalytic inhibitor of IκB kinase (IKK) subunits (9) . The resulting IKK activation induces expression of multiple cytokines and chemokines. In this context, TAK1 was shown to be a central mediator in proinflammatory cytokine signaling, including TRAF6/TNF (10). Induction of GVHD in Cx3cr1 creER Tak1 fl/fl mice that lack TAK1 in microglia but not peripheral macrophages (Supplemental Figure 1 TNF production, we observed lower TNF expression in microglia of Cx3cr1 creER Tak1 fl/fl mice compared with littermate controls ( Figure 5 , I and J).
To analyze whether the CX3CR1-Cre system was specifically active after tamoxifen treatment, we used Cx3cr1 creER Tak1 fl/fl mice without tamoxifen treatment. There was no evidence for TAK1 deletion in Cx3cr1 creER Tak1 fl/fl mice without tamoxifen treatment (Supplemental Figure 1 , I and J). Also, there was no evidence for Cre expression in neurons of Cx3cr1 creER R26-Tomato reporter mice (Supplemental Figure 1K ). We observed no reduction of TNF or MHC-II in the Cx3cr1 creER Tak1 fl/fl mice that were not treated with tamoxifen after allo-HCT in comparison with Tak1 fl/fl mice that underwent allo-HCT (Supplemental Figure 2, A and B) .
The TAK1-deletion effect was restricted to the CNS, as GVHD-related mortality was not different when Cx3cr1 creER Tak1 fl/fl mice and littermates were compared ( Figure 5K ). Consistent with similar survival rates, the histopathological scoring of peripheral GVHD organs including small intestines, large intestines, and liver was not different between Cx3cr1 creER Tak1 fl/fl mice and littermate controls (Supplemental Figure 2 , C-E).
However, consistent with improved neurocognitive function, Cx3cr1 creER Tak1 fl/fl mice exhibited higher exploratory activity in the elevated plus maze test compared with littermate controls (Figure 5L) . Additionally, the novel object recognition test showed that Cx3cr1 creER Tak1 fl/fl mice had a better recognition memory compared with controls ( Figure 5M ). The differences in motoric function were not due to a general weakness of the mice, as the Cx3cr1 creER Tak1 fl/fl mice and controls exhibited similar grip strength ( Figure 5N) . Also, the neurocognitive differences were not due to a loss of vision, as the Cx3cr1 creER Tak1 fl/fl mice and controls exhibited similar results in the visual cliff test (Supplemental Figure 2F) .
These findings indicate that a selective deletion of TAK1 in CX3CR1 + microglia reduces inflammatory T cell infiltration into the brain, reduces numbers of Iba-1 + microglia, reduces MHC-II and TNF expression by microglia, and promotes neurocognitive function of mice developing GVHD without blocking peripheral GVHD.
Therapeutic TAK1 inhibition reduces inflammatory features of microglia during CNS-GVHD. To test for a potentially translational approach, we next treated mice with 2 different TAK1 inhibitors, takinib and (5Z)-7-oxozeaenol, in comparison with vehicle and then analyzed the CNS. We observed that TAK1 inhibition reduced the expression of MHC-II and TNF compared with the vehicle treatment ( Figure 6 , A-D). Additionally, TAK1 inhibition reduced the number of CD3 + T cells and Iba-1 + microglia in comparison with the vehicle group ( Figure 6 , E-I).
In addition to the decreased accumulation of total CD3 + T cells in the CNS upon TAK1 inhibition, we observed a decrease of Figure 3E ).
To understand why T cell infiltration was reduced in the CNS of mice that were treated with the TAK1 inhibitor or lacking TNF in CX3CR1 + cells, we studied molecules that are required for T cell extravasation. T cell adhesion to endothelial cells is mediated via VCAM-1 and ICAM-1 (11) , which then allows T cells to exit the vessel and enter the CNS.
We found reduced expression of VCAM-1 and ICAM-1 on endothelial cells (CD31 + CD105 + ) in the CNS of mice treated with takinib compared with mice treated with vehicle ( Figure 7 , A-E, and Supplemental Figure 4 ). We also found a reduced number of VCAM-1 + endothelial cells in the CNS of Cx3cr1 creER Tnf fl/mice (TNF deletion) compared with Tnf fl/-(no TNF deletion) mice (Figure 7, F and G) . These findings support the concept that the TAK1/TNF axis promotes VCAM-1 expression on endothelial cells. Genetic deletion of TNF or TAK1 inhibition reduces VCAM-1 expression during CNS-GVHD.
These findings in the CNS of TAK1 inhibitor-treated mice were connected to improved neurocognitive function, as the TAK1 inhibitor group exhibited more frequent entries into open arm in the elevated plus maze test compared with the vehicle group ( Figure  7H ). The novel object recognition test showed that the TAK1 inhibitor-treated group performed better compared with the vehicletreated group ( Figure 7I ). The differences in motoric function were not due to a general weakness of the TAK1 inhibitor-treated mice, as they exhibited similar grip strength (Supplemental Figure  5A) . Also, the neurocognitive differences were not due to a loss of vision, as the TAK1 inhibitor-treated mice and the vehicle-treated mice exhibited similar results in the visual cliff test (Supplemental Figure 5B ). In order to be potentially applicable in a clinical setting, engraftment of the donor hematopoietic system is essential. We observed that the TAK1 inhibitor-treated mice and the vehicle-treated mice exhibited similar engraftment (Supplemental Figure 5C ), while there was no change of GVHD scores in the small and large bowels but a reduced liver GVHD score in the TAK inhibitor-treated mice (Supplemental Figure 5 , D-F). TAK1 inhibitor-treated animals exhibited a lower frequency of monocyte infiltrates or activated microglia compared with vehicle-treated mice (Supplemental Figure 5 , G and H).
To evaluate the impact of takinib treatment on graft-versus-leukemia (GVL) activity, we used a genetic acute myeloid leukemia (AML) model (FLT3-ITD/MLL-PTD) and a cell line-based AML model (WEHI-3B) (12) . The AML cells were on the same genetic background as the recipient mice to mimic the clinical situation. In both models the group that received T cells experienced improved survival compared with the group that received AML cells and bone marrow only, indicating the GVL effect. The treatment with takinib did not reduce the GVL effect in both leukemia models (Figure 7 , J and K).
Microglia cells expand and produce TNF in human CNS-GVHD. To understand whether patients developing acute GVHD had changes in microglia cells comparable to those we had observed in mice, we studied the brains of patients who died after allo-HCT. We observed an increased number of Iba-1 + microglia in patients who developed acute GVHD compared with patients who underwent allo-HCT but did not develop GVHD. The increase was found in gray and white matter of the frontal lobe (Figure 8 , A-D). TNF in microglia was visualized by IHC for Iba-1 and TNF. The jci.org Volume 130 Number 3 March 2020
GVHD grade II-IV was independently associated with increased risk of noninfectious neurological complications with a hazard ratio of 3.3 and P less than 0.00001. Despite these reports, it is important that other diseases such as progressive multifocal leukoencephalopathy or viral encephalitis (e.g., herpes simplex virus, CMV, or varicella zoster virus) be ruled out before CNS-GVHD is diagnosed in a patient with GVHD developing neurological symptoms.
Discussion
The clinical picture of acute GVHD is often connected to neurological deficits in patients, morphological CNS white matter changes detectable by MRI, and intraparenchymal lymphocytic infiltration of the brain upon autopsy (5, 14) .
While previous work had shown that T cells contribute to CNS-GVHD (2, 3), the role of microglia cells had not been studied. We have previously extended the concept that GVHD is a purely T cell-mediated disease by showing that myeloid cells including neutrophils (15) and monocytes (16) contribute to GVHD development by tissue damage and MHC-II-dependent antigen presentation (17) . Here we show that microglia, a prototypical tissue macrophage population in the CNS, contribute significantly to the pathogenesis of CNS-GVHD.
Our first observation that microglia cells exhibit an activated phenotype during GVHD with reduced numbers of branches is consistent with findings in CNS autoimmunity models describing this phenotype when experimental autoimmune encephalomyelitis (EAE) evolves (6) . Our observation that CX3CR1 expression on microglia declined during GVHD is consistent with reports showing high CX3CR1 expression on resting microglia and a decline upon microglia activation (7) . The morphological microglia changes occurred in parallel with the upregulation of MHC-II and CD80, which allow for antigen presentation to donor T cells and costimulation of these T cells, respectively. In agreement with this concept in CNS-GVHD, it was shown that non-hematopoietic antigen-presenting cells also contribute to peripheral GVHD, while classical dendritic cells were dispensable (18) . Comparable to our findings in CNS-GVHD, others have shown in EAE that myeloid antigen-presenting cells are recruited to the brain, which correlated with disease severity (19, 20) , and that these cells present antigen to autoreactive T cells to mediate CNS inflammation (21) .
In addition, we found increased levels of TNF in micro glia during CNS-GVHD. TNF has direct cytotoxic effects on cells during GVHD (22) , which could be responsible for the neuronal death observed previously after allo-HCT (2) . Consistent with the concept that TNF plays a major role in CNS-GVHD, we found that T cell infiltration into the CNS and MHC-II expression on microglia were reduced when microglia cells were deficient in TNF.
We observed that TNF also increased in the syn-HCT group, although not to the same extent as in the allo-HCT group, which is likely due to the total-body irradiation-induced damage. The observation that CD3 + T cells were not increased in the syn-HCT groups indicates that a higher level of TNF may be required to attract T cells to the CNS, as was the case in the allo-HCT group.
Our finding that Th1 and Th17 cells declined in the CNS upon TAK1 inhibition is compatible with findings in other models of frequency of TNF and Iba-1 double-positive microglia was significantly increased in patients that had developed acute GVHD (Figure 8, E and F) . In agreement with CNS-GVHD, these patients also exhibited higher CD3 + T cell frequencies (Figure 8, G and H) . These observations made in patient samples indicate that major findings made in the mouse model may also hold true for humans.
In addition, we reviewed the literature for cases of CNS-GVHD and listed the reports in Supplemental Table 4 . In the majority of the cases of CNS-GVHD the diagnosis was histology-proven, supporting the concept that CNS-GVHD is a clinically relevant complication.
To further elucidate the potential clinical relevance of CNS-GVHD, we analyzed the frequency of neurological symptoms that occurred at the same time that a patient developed acute GVHD grade II-IV in 503 patients undergoing allo-HCT at Freiburg University Hospital, Germany. Neurological symptoms related to infection or vascular events were not included. The time interval included the first 2 years after allo-HCT because acute GVHD occurs in 90% of all cases within this time interval. The multivariable logistic regression analysis included presence of acute GVHD grade II-IV, donor type (MRD, MUD, MMUD, haploidentical donor), conditioning (myeloablative versus reduced-intensity), sex, and age over 40 versus under 40 years as possible risk factors for the occurrence of neurological complications. We found that development of acute GVHD grade II-IV was independently associated with increased risk of noninfectious neurological complications with an odds ratio of 491 and P less than 0.0001 (Supplemental Tables 5 and 6 ). Our results are consistent with a recent retrospective analysis on the incidence and risk factors of noninfectious neurological complications in 971 consecutive patients with hematological malignancies undergoing allo-HCT (13) . The authors found in multivariable analysis that development of acute TNF axis was connected to VCAM-1 expression on endothelial cells. Genetic deletion of TNF or TAK1 inhibition reduced VCAM-1 expression during CNS-GVHD. T cell adhesion to endothelial cells is mediated via VCAM-1, which then allows T cells to exit the vessel and enter the CNS (11), supporting the concept that TAK1 inhibition reduced TNF and, subsequently, VCAM-1 expression, thereby decreasing donor T cell infiltra-CNS inflammation. Th1 and Th17 cells were shown to be proinflammatory and to promote the development of EAE (23, 24) .
In our studies we also identify increased TAK1 activation and NF-κB/p38 MAPK signaling activity in microglia during GVHD and show a functional role for TAK1, as selective Tak1 deletion in microglia reduced TNF production, T cell infiltrates in the CNS, and MHC-II levels. Mechanistically, the TAK1/ Statistics. For the sample size in the murine GVHD survival experiments, a power analysis was performed. A sample size of at least n = 8 per group was determined by 80% power to reach a statistical significance of 0.05 to detect an effect size of at least 1.06. Differences in animal survival (Kaplan-Meier survival curves) were analyzed by Mantel-Cox test. The experiments were performed in a nonblinded fashion except for the GVHD severity scoring, the analysis of human tissue specimens, and behavioral experiments with the knockout mice. To obtain unbiased data, a pathologist blinded to both the genotype and the treatment group performed the histopathological scoring of GVHD severity. Only after finalization of the quantitative GVHD severity scores were the samples allocated to their genotypes/treatment group. Analysis of human brain specimens was also performed in a blinded manner, and the samples were allocated to the group after finalization of the analysis. All samples or mice were included in our analysis.
For statistical analysis of 2 groups, an unpaired 2-tailed Student's t test was applied. All data were tested for normality applying the Kolmogorov-Smirnov test. If the data did not meet the criteria of normality, the Mann-Whitney U test was applied. If more than 2 groups were analyzed, we used the Kruskal-Wallis test if nonparametric testing was suggested, and we performed a 1-way ANOVA in case of normally distributed data. Statistical analysis was performed using GraphPad Prism (GraphPad Software). Data are presented as mean and SEM (error bars). Differences were considered significant when the P value was less than 0.05.
Study approval. The study included formalin-fixed and paraffin-embedded (FFPE) tissue specimens of different brain regions from patients who died of causes unrelated to allo-HCT, patients who died after allo-HCT without GVHD, and patients who died after allo-HCT and had GVHD (grade 3-4). The study was approved by the local ethics committee (protocol 547/14; Ethics Committee, University of Freiburg). Patients who underwent autopsy within a time period of 16 years (2001-2017) at the Institute of Neuropathology, Freiburg University Hospital, Germany, were analyzed. Patient characteristics are shown in Supplemental Tables 1-3. A retrospective analysis of 503 patients undergoing allo-HCT at Freiburg University Medical Center with a follow-up of at least 12 months was performed. The analysis was approved by the Institutional Ethics Review Board of Freiburg University Medical Center (protocols 10024/13, 26/11, and 509/16). Written informed consent was obtained from each patient. All analyses of human data were carried out in compliance with the relevant ethical regulations. The analysis included neurological symptoms that occurred at the same time that a patient developed acute GVHD grade II-IV. Neurological symptoms related to infection or vascular events were not included. The observation time interval included the first 2 years after allo-HCT because acute GVHD occurs in 90% of all cases within this time interval. The multivariable logistic regression analysis included presence of acute GVHD grade II-IV, donor type (MRD, MUD, MMUD, haploidentical donor), conditioning (myeloablative versus reduced-intensity conditioning), sex, and age over 40 versus under 40 years as possible risk factors for the occurrence of neurological complications. Patient characteristics are provided in Supplemental Tables 5 and 6 .
Animal protocols (protocols G-13/045, G13-116, G-15/018, G-17/063, X-13/07J, and X-15/10A) were approved by the Regierungspräsidium Freiburg (regional council), Freiburg, Germany (Federal tion into the CNS. Consistent with a functional role for TAK1 in CNS-GVHD, the neurocognitive function of mice lacking TAK1 in microglia was improved. Besides the genetic Tak1 deletion approach, we also show that pharmacological TAK1 inhibition reduced TNF production and MHC-II expression by microglia cells and improved neurocognitive activity. Our previous work using Janus kinase inhibitors has shown the high potential of kinase inhibition to prevent or treat GVHD in mice (25) and patients (26) . Our findings are potentially clinically relevant as treatment with the TAK1 inhibitor takinib did not affect GVL effects in 2 AML models. In agreement with the functional role of microglia-derived TNF for CNS-GVHD in mice, we observed an increase of the microglia cell number and their TNF production in the CNS of patients who developed GVHD.
In aggregate, we report a role for microglia in CNS-GVHD and identify the TAK1/TNF/MHC-II axis as a central mediator of this disease. Additionally, we provide a serine-threonine kinase inhibitor-based approach against GVHD-induced neurotoxicity identified based on RNA-Seq analysis of the CNS.
Methods
Mice. C57BL/6 (H-2Kb, Thy-1.2) and BALB/c (H-2Kd, Thy-1.2) mice were purchased either from Janvier Labs (France) or from the local stock of the animal facility at the University of Freiburg. Tak1 fl/fl and Cx3cr1 creER Tak1 fl/fl (6) , Cx3cr1 creER R26-yfp (6), CCR2 -/- (27) , and Cx3cr1 creER R26-Tomato reporter mice were bred in the animal facility at the University of Freiburg. Tnf fl/and Cx3cr1 creER Tnf fl/- (27) mice were bred at the Weizmann Institute of Science, Rehovot, Israel. Mice were used between 6 and 14 weeks of age, and only female or male donor/ recipient pairs were used. Bone marrow transplantation model and histopathology scoring. Bone marrow transplantation experiments were performed as previously described (12, 28) . Briefly, recipients were exposed to lethal irradiation of 9-11 Gy. CD4 + and CD8 + T cells were isolated from donor spleens and enriched by positive selection with the MACS cell separation system (Miltenyi Biotec) according to the manufacturer's instructions. Anti-CD4 and anti-CD8 MicroBeads were used. Alternatively, T cells were isolated from donor spleens by negative selection (Pan T Cell Isolation Kit-II), with the MACS cell separation system (Miltenyi Biotec) according to the manufacturer's instructions. CD4 + /CD8 + T cell purity was at least 90% as assessed by flow cytometry (data not shown). To induce GVHD, 5 × 10 6 bone marrow cells and CD4 + /CD8 + T cells from an MHC-mismatched donor (allogeneic stem cell transplantation) were given at a dosage of 3 × 10 5 (C57BL/6-derived into BALB/c) or 8 × 10 5 (BALB/c-derived into C57BL/6) i.v. on day 0. For behavioral studies, a sublethal dose of 5 × 10 5 BALB/c-derived T cells was used. As a control, syngeneic stem cell transplantation (syn-HCT) was performed by injection of the same amount of bone marrow and T cells from a donor mouse with the same genetic background as that of the recipient. Slides of small intestine, large intestine, and liver specimens collected after allo-HCT were stained with H&E and scored by an experienced pathologist blinded to the treatment groups. GVHD severity was determined according to a previously published histopathology scoring system (29) .
RNA-Seq data were deposited in the NCBI's Gene Expression Omnibus database (GEO GSE141663). All antibodies are listed in Supplemental Table 7 .
